A novel small molecule inhibitor of the IGF-1R/IR/ALK triad, GSK1838705A, has shown antitumor activity in human tumor models and should help elucidate the relationship of IGF-1R pathway activation in ALK-positive tumors noted within subtypes of NSCLC, lymphoma, and sarcoma [115]. This evidence concerns the gene ALK and sarcoma.